Regeneron : EYLEA HD Shows Sustained Vision Gains In Wet AMD Patients At 3 Years

(RTTNews) – Regeneron Pharmaceuticals Inc. (REGN) announced positive three-year (156-week) results for EYLEA HD (aflibercept) Injection 8 mg in patients with wet age-related macular degeneration or wAMD from an extension study of the Phase 3 PULSAR trial.

Source link